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SUMMARY · Amenorrhea is one of the most common symptoms in  the woman’s health pathol-
ogy. It can be caused by anatomical defects of the outflow tract (uterus, cervix, vagina), thus being in
the gynecologist’s domain, or can be observed in gonadal dysgenesis (Turner’s syndrome), hypopitu-
itarism (Sheehan’s syndrome), prolactin-secreting pituitary tumors, Cushing’s syndrome, hyperthy-
roidism, stress, anorexia nervosa, polycystic ovaries, and in women upon discontinuation of oral con-
traceptives, especially if they have a history of prior menstrual irregularities. Endocrine abnormali-
ties may also be due to changes in target tissue responses to hormones. These disorders can occur by
a variety of mechanisms. Endocrine glands may be injured or destroyed by neoplasia, infections,
hemorrhage, autoimmune disorders, and many other causes. Menopause, pregnancy and lactation
are the most common causes of ammenorrhea. Hypothalamic lesions resulting in impaired secretion
of releasing hormones may manifest themselves by pituitary dysfunction, which in turn leads to func-
tional abnormalities of its various target organs. Extraglandular disorders can result in hormone de-
ficiency and become manifest with amenorrhea as one of the symptoms. Assessment of the patient’s
endocrine status relies on the findings from the history, physical examination and laboratory testing.
The latter can include measurement of hormone levels of their metabolites in plasma or urine either
in basal state or in response to provocative testing. For endocrine deficiency syndromes, hormones
are generally administered to counteract the deficiency. In hormone excess syndromes, a variety of
approaches have been used. Hyperfunctioning tumors are removed when possible, and sometimes
hyperplastic glands are extirpated. In other cases, drugs are given to block hormone production.
Menopause related osteoporosis is the leading health problem associated with amenorrhea and should
be treated as early as possible, i.e. from the beginning of the period of menses disappearance.
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Introduction
Various physical, chemical and physiological stressors
can provoke the cessation of menses. The most common
are normal causes such as pregnancy, lactation and natu-
ral menopause. The genetic pattern is unknown. The in-
cidence of primary amenorrhea is 0.3%, and of second-
ary amenorrhea 3.3%. An attempt has been made here-
with to explain the reasons that lead to amenorrhea and,
which is very important, the real risk for woman’s health
associated with amenorrhea.
The absence of menarche by age 16 irrespective of the
presence or absence of secondary sexual characteristics is
termed primary amenorrhea. The cessation of menses for
longer than 6 months in a patient who has previously
menstruated is termed secondary amenorrhea. There are
disorders that can cause both primary and secondary
amenorrhea (anatomical defects of the outflow tract, ova-
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rian failure, chronic anovulation with or without the pres-










· physiological: menopause, pregnancy, lactation,
corpus luteal cyst
· suppression of the hypothalamic-pituitary axis,
post-pill amenorrhea, stress, intercurrent illness,
weight loss, low body mass index
· pituitary disease: ablation of the pituitary gland,
Sheehan’s syndrome, prolactinoma
· uncontrolled endocrinopathies: diabetes, hypo- or
hyperthyroidism




· endometrial ablation (Asherman’s syndrome)
· drug therapy: systemic steroids, danazol, GRH-RH
analogs, antipsychotics, OCPs
· premature ovarian failure
Primary amenorrhea is the physiologic end of fertil-
ity in women. It is a physiologic state in the life of every
woman, however, this ‘physiologic disease’ carries a lot of
problems that are not physiologic by nature and cause
considerable difficulties in a woman’s life. The develop-
ment of endocrinology has contributed greatly to the
understanding of the very specific pathophysiologic
mechanism of ovarian hormone regulation. Low estrogen
and progesterone levels in menopausal women predispose
to a faster development of some chronic diseases such as
elevated blood pressure, atherosclerosis and osteoporosis.
A low level estrogen/progesterone replacement therapy
introduced on time could be the mode of protection in
menopausal women.
Also, many congenital anatomical defects of the outflow
tract include congenital defects of the vagina, imperforate
hymen, transverse vaginal septum, cervical stenosis, intrau-
terine adhesions, absence of the vagina or uterus, and uter-
ine maldevelopment. These conditions are usually diag-
nosed by physical examination and confirmed by demon-
strating failure of bleeding following administration of es-
trogen plus progesterone for 21 days1. Pelvic ultrasonog-
raphy, magnetic resonance imaging (MRI), hysterosalpin-
gography or hysteroscopy may also be helpful in defining
the defect. The causes of ovarian failure include gonadal
dysgenesis, resistant ovary syndrome, and premature ova-
rian failure. An elevated plasma level of follicle stimulat-
ing hormone (FSH) confirms the diagnosis. Women with
chronic anovulation fail to ovulate spontaneously but have
the capability of ovulating with appropriate therapy. In
some women with this condition, total estrogen production
is adequate, but it is not secreted in a cyclic fashion. In oth-
ers, estrogen production is deficient2-4. Women who have
adequate estrogen production and demonstrate withdrawal
bleeding after progesterone challenge, usually have polycys-
tic ovarian syndrome. Other causes include hormone-se-
creting ovarian and adrenal tumors. Women with deficient
or absent estrogen production, and thus absent withdrawal
bleeding after progesterone administration usually have
hypogonadotropic hypogonadism due to organic or func-
tional disorders of the pituitary or central nervous system
(CNS) such as brain tumors (especially prolactin-secreting),
or primary hypopituitarism5.
Hypothalamic hypogonadism due to hypothalamic
disease can cause pituitary hyper- and/or hypofunction of
a varying severity. A mild disease can cause subtle alter-
ation of the feedback loops and timing, so that, for ex-
ample, the integration of signals necessary for menstrual
cycling is lost, resulting in ‘hypothalamic’ amenorrhea6.
The disorders causing these conditions may be pri-
mary (congenital defects) or acquired, may be restricted
to gonadotropin-releasing hormone (GnRH) or may also
cause the loss of other hormones. Prepubertal lesions re-
sult in failure of the onset of puberty, or in incomplete
progression of puberty if the defect is partial. The most
common congenital lesion causing prepubertal GnRH
deficiency is Kallman’s syndrome · hyposmia or anosmia
due to hypoplasia of the olfactory bulb along with absent
GnRH secretion. Among females with primary amenor-
rhea due to GnRH deficiency, 37% were found to have
associated anosmia and thus Kallman’s syndrome. When
12 of these women were studied for gonadotropin pulsa-
tile secretion, 11 had no pulsations.
Other hypothalamic lesions associated with impaired
GnRH production, thus leading to hypogonadotropic
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hypogonadism include craniopharyngioma, germinoma,
glioma, teratoma, endodermal sinus tumors, tuberculosis,
sarcoidosis, and metastatic tumors.
Craniopharyngiomas are common tumors of the hy-
pothalamus, arising from remnants of Rathke’s pouch7.
They consist of cysts alternating with stratified squamous
epithelium. Although presenting at any age, craniophar-
yngiomas are most common in children. They are often
calcified and can therefore be visualized by conventional
skull films8. The symptoms include headache, vomiting,
visual impairments, seizures, hypopituitarism (50% -
70%), and hyperprolactinemia. Hypopituitarism is due to
the absence or destruction of the pituitary9. Up to 32%
of women experiencing hemorrhage and vascular collapse
during delivery will develop some degree of hypopituitar-
ism. The extent of pituitary necrosis and subsequent hy-
popituitarism are related to the severity of the hemor-
rhage10. The most important clue that pituitary necrosis
has occurred is inability to lactate in the postpartum pe-
riod and failure of cyclic menstruation restitution. Today,
the most common cause of hypopituitarism is pituitary
tumor11.
Secondary hypopituitarism is due to the lack of stimu-
lation of pituitary hormone secretion caused by organic
or functional disorders of the vascular and/or neural con-
nections with the brain at the level of the pituitary stalk,
hypothalamus, or extrahypothalamic CNS.
Pituitary adenomas are the most common tumors af-
fecting the hypothalamus, accounting for more than 90%
of all pituitary neoplasms. Hyperprolactinemia occurs in
about half of these tumors, caused primarily by disinhi-
bition by the hypothalamus, with decreased dopamine
reaching the pituitary12,13.
Suprasellar dysgerminomas are said to arise from
primitive germ cells that have migrated to the CNS dur-
ing fetal life and are structurally identical to germ cell
tumors of gonads. They usually present in children, in
whom they most commonly cause growth retardation due
to hypopituitarism, then diabetes insipidus, visual prob-
lems, and hyperprolactinemia (over 50%). Some 10% of
patients have precocious puberty caused by the produc-
tion of human chorionic gonadotropin (HCG) by the
tumor.
Head trauma can cause defects ranging from isolated
adrenocorticotropic hormone (ACTH) deficiency to pan-
hypopituitarism with diabetes insipidus. Within the first
72 hours of trauma, blood levels of growth hormone
(GH), luteinizing hormone (LH), ACTH, thyroid-
stimulating hormone (TSH) and prolactin (PRL) may be
elevated (perhaps as the result of an acute release). Dur-
ing prolonged observation, these levels fall and patients
either return to normal or develop hypopituitarism, except
for persistent PRL elevation in many cases14. These pa-
tients may or may not have associated loss of conscious-
ness, but other neurologic abnormalities are common. In
patients dying from head injury, anterior pituitary infarc-
tion was found in 16%, posterior pituitary hemorrhage in
34%, and hypothalamic hemorrhage or infarction in 42%
of cases15.
Whole brain irradiation for intracranial neoplasms
results in hypothalamic dysfunction in 1.25% of patients,
as evidenced by endocrine abnormalities and behavioral
changes. The most common endocrine abnormality is
hyperprolactinemia, however, when radiotherapy is tar-
geted to the hypothalamic area or to the pituitary, a higher
10-year rate of clinically significant hypopituitarism has
been recorded16.
Hyperprolactinemia is the second major hypothalamic
cause of amenorrhea and anovulation and female infertil-
ity, accounting for about 20% of cases. Hyperprolactinemia
can also cause a decrease in GnRH secretion and cessation
of pulsatile secretion17. When it occurs before puberty, it can
prevent the onset of puberty and should always be looked
for in this setting. Prolactin is the only hormone whose
secretion is mainly under hypothalamic inhibitory control
mediated by the release of dopamine into the portal pitu-
itary circulation. Disruption of this system by a hypotha-
lamic tumor, infiltrative disease (e.g., sarcoidosis), or sur-
gical or traumatic stalk section can affect hypothalamic
function, causing modest hyperprolactinemia.
Pituitary prolactinoma accounts for 50% of cases of
hyperprolactinemia18,19. These tumors are classified into
microadenomas (less than 1 cm in diameter) and macro-
adenomas (less common in women; they may extend
suprasellarly, parasellarly or anterioinferiorly into the sphe-
noid sinus). The symptoms are oligo- or amenorrhea, ga-
lactorrhea, mild obesity, hirsutism, frictional dyspareunia,
and loss of libido. The fairly good correlation between the
level of prolactin and size of adenoma considerably helps
in reaching the diagnosis, as serum levels greater than 200
ng/ml are almost always associated with prolactinoma, fre-
quently macroadenoma20.
Phenotiazines and other psychotropic agents antago-
nizing hypothalamic dopaminergic pathways are associ-
ated with mild to moderate elevations of prolactin con-
centration (up to four times normal). Amenorrhea occurs
in 22% of female psychiatric patients with drug induced
galactorrhea. Other medications associated with
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hyperprolactinemia are metoclopramide, H2 histamine
antagonists, calcium channel blockers, alfa methyldopa,
and oral contraceptives. The symptoms generally resolve
with medication discontinuation21.
Idiopathic hyperprolactinemia is defined as hyper-
prolactinemia that occurs in the absence of any recognized
pituitary, hypothalamic or other cause, and may manifest
with amenorrhea, galactorrhea, impotence, infertility, and
loss of libido.
Cushing’s syndrome results from prolonged exposure
of the body to high levels of glucocorticoid hormones. The
cause can be exogenous, resulting from the administration
of glucocorticoids or corticotropin (ACTH), or endog-
enous, secondary to increased secretion of cortisol or
ACTH. It is most commonly iatrogenic, caused by glu-
cocorticoid therapy22. Cortisol regulation involves feed-
back loops on the pituitary gland and hypothalamus.
Spontaneous (endogenous) Cushing’s syndrome can re-
sult from ACTH excess (ACTH dependent), which can
arise from the pituitary gland or ectopic ACTH-secret-
ing tumors, or from autonomous secretion of cortisol
(ACTH independent) by a cortisol-secreting adrenal tu-
mor or ‘micronodular’ adrenal glands. Amenorrhea is in
part a consequence of androgen suppression of gonadot-
ropin secretion. Approximately 70% of these cases of
hypercortisolism are secondary to ACTH hypersecretion
from the pituitary gland, a condition called Cushing’s
disease23.
Pituitary adenomas are present in a vast majority of
patients1. Hypersecretion of cortisol from the adrenal
glands accounts for approximately 10% - 20% of cases of
Cushing’s syndrome. The underlying cause is adrenal
adenoma in 50% - 60%, and adrenocortical carcinoma in
20% - 25% of cases. Bilateral adrenal hyperplasia accounts
for the remaining 20% - 30% of cases.
Ectopic secretion of ACTH, referred to as ectopic
ACTH syndrome, causes about 15% of cases of Cushing’s
syndrome24,25. In case of ectopic ACTH syndrome caused
by ACTH hypersecretion from nonpituitary tumors, these
tumors contain immunoreactive and bioactive ACTH,
and they also secrete ACTH in vitro26. The tumors most
commonly causing ectopic ACTH syndrome are oat cell
carcinoma of the lung, pancreatic islet cell carcinoma,
carcinoid tumors (lung, gut, thymus, pancreas, ovary),
thyroid medullary carcinoma, pheochromocytoma, and
related tumors27.
Glucocorticoid-producing adrenal tumors arise de
novo and autonomously hypersecrete cortisol and suppress
the hypothalamic-pituitary axis, corticotropin-releasing
hormone (CRH) and circulating plasma ACTH levels.
Adrenal adenomas causing Cushing’s syndrome usually
secrete only cortisol in significant excess28.
The onset of clinical progression of an ACTH-secret-
ing pituitary adenoma after bilateral adrenalectomy for
Cushing’s disease is called Nelson’s syndrome29. After
adrenalectomy, the suppressive effect of cortisol is no
longer present, ACTH secretion increases, and the ad-
enoma may progress. The incidence of Nelson’s syndrome
ranges from 5% to 78%. About 30% of patients adrena-
lectomized for Cushing’s syndrome have been found to
develop classic Nelson’s syndrome. Another 50% develop
evidence of a microadenoma without marked progression,
and about 20% never develop progressive pituitary tumor.
The tumors in patients with classic Nelson’s syndrome are
among the most aggressive and rapidly growing of all pi-
tuitary tumors. These patients present with hyperpigmen-
tation and manifestations of an expanding intrasellar mass
lesion, usually within months to 2 years from adrenalec-
tomy. Sellar enlargement, extrasellar extension, headache,
visual field defects, and hypopituitarism are common.
Invasion of the cavernous sinus or cranial fossae may lead
to extraocular muscle palsies and other neurologic defects.
These tumors can occasionally be frankly malignant with
local invasion and extracranial metastases, and there is a
high incidence of pituitary apoplexy (spontaneous hem-
orrhagic infarction of the tumor)30.
The major ovarian causes of amenorrhea are hyper-
androgenism, from internal to external sources, and ova-
rian failure due to normal or early menopause31-33. Pre-
mature ovarian failure can be defined as a syndrome of
amenorrhea, hypoestrogenism, and elevated serum gona-
dotropin concentrations occurring before age 40. Ovarian
failure occurs when the supply of oocytes and surround-
ing follicles is depleted. The lack of ovarian function leads
to absolute estrogen deficiency, endometrial atrophy, and
absence of menstruation34. This state can be idiopathic,
associated with autoimmune ovarian destruction or karyo-
typic abnormalities, or induced by radiation or chemo-
therapy35. It is estimated that an autoimmune disease is
present in approximately 30% of these patients, and as-
sociated with other autoimmune diseases, especially
Hashimoto’s thyroiditis and Addison’s disease. Physical
agents such as pelvic surgery, viral (mumps), oophoritis,
gonadal irradiation, chemotherapy (cyclophosphamide or
busulfan), and cigarette smoking are also known to cause
transient premature ovarian failure36.
The clinical and hormonal features are similar to those
of the normal menopause and commonly develop over a
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period of several years. Half of the patients present with
clinical features of hypoestrogenism (mainly vaginal dry-
ness and hot flushes), while secondary sexual character-
istics are usually normal. If the condition develops around
the time of menarche, the secondary sexual characteris-
tics may be underdeveloped. As after the normal meno-
pause, serum gonadotropin concentrations are elevated
and hyperresponsive to GnRH, serum FSH levels may
fluctuate in and out of the normal range, and serum es-
tradiol levels may rise to the midfollicular range37. Nei-
ther clinical features nor the degree of FSH concentration
elevation predicted which subjects would resume ovarian
function. Little is known about the natural history of pre-
mature ovarian failure, although spontaneous resumption
of menses and fertility may occur in some women. Ge-
netic chromosomal abnormalities, particularly variants of
gonadal dysgenesis, may present with premature ovarian
failure. However, the majority of subjects have normal
46,XX karyotype. A family history of premature ovarian
failure is found in 10% of subjects. Reports of vertical
transmission of the trait are consistent with autosomal
dominant or sex-linked inheritance.
Occult ovarian failure is a new syndrome of the clini-
cal triad. Autoantibodies to adrenal or thyroid glands are
present in 50%, and antiovarian antibodies in 40% of pa-
tients. A syndrome of ‘incipient ovarian failure’ has also
been described, where inhibin levels are below the nor-
mal range and FSH is more markedly elevated than in
occult ovarian failure38.
In anorexia nervosa, amenorrhea occurs with reduc-
tion of body weight and fat. In severe cases, body weight
may be as low as 25 kg. Treatment occasionally involves
hospitalization for severe cachexia but primarily includes
intensive psychotherapy. Rates of successful treatment
vary but are improved by early diagnosis. Mortality rates
of 0% to 19% have been reported.
Polycystic ovary syndrome is caused by inappropriately
enhanced estrogen feedback or disturbance in the normal
dopaminergic control of GnRH. There is a strong famil-
ial component to polycystic ovary syndrome. The syn-
drome includes oligo- or amenorrhea, infertility, hirsut-
ism, obesity, and enlarged polycystic ovaries. Diagnosis is
based on typical clinical features associated with an el-
evated LH/FSH ratio and increased plasma androgen
levels. On ultrasonography, polycystic ovary syndrome is
common in asymptomatic first-degree relatives of patients
presenting with the syndrome. Irregular cycles in polycys-
tic ovary syndrome can be controlled by a combination of
an oral contraceptive and progestogen. Therefore, this
common condition has heterogeneous clinical, anatomi-
cal and biochemical features.
Nutritional amenorrhea is caused by weight loss be-
low 10% - 15% of ideal body weight. Many women of re-
productive age are engaged in some kind of exercise, and
most benefit from it in terms of improved exercise capac-
ity, body weight control, and reduction of cardiovascular
risk factors. However, excessive exercise at a critical time
during development may delay puberty and menarche.
Exercise alone does not induce amenorrhea. It appears
that amenorrhea only occurs when there is relative caloric
deficiency due to inadequate nutritional intake for the
amount of energy expended. The hormone leptin is se-
creted by fat cells in proportion to body fat stores. Exer-
cising women with amenorrhea lose the normal diurnal
rhythm of leptin, raising the possibility that the diurnal
rhythm is important for the maintenance of adult human
reproductive function. Weight loss, particularly reduction
in the percentage of body weight as fat, may occur if ex-
ercise programs are too difficult or dietary intake is inad-
equate (athletes, students matched for career stress). Re-
sumption of menstruation and fertility usually accompa-
nies the weight regain. If weight gain is not practicable,
consideration should be given to replacement therapy to
avoid the long-term sequels of hypoestrogenism.
Primary hypothyroidism, renal failure and liver cirrho-
sis as systemic diseases, and some local factors such as re-
petitive nipple stimulation, irriatative chest wall diseases
(thoracic scarring or herpes zoster) also are reasons that
lead to amenorrhea.
Diagnosis
Diagnostic procedures and studies must address two
questions:
1) is pituitary hormone secretion diminished?, and
2) is the disorder of pituitary or nonpituitary origin?
Different etiologies have different clinical presenta-
tions. Difficulties in clinical diagnosis and especially in
therapy are discussed below.
· Differential diagnosis
· Laboratory
If pregnancy test is negative, the following parameters
should be determined: serum prolactin, FSH, LH, TSH,
and blood sugar
· Pathologic findings
· Special tests: progesterone challenge test
· Imaging: ultrasonography, radiologic evaluation
(CT, MRI)
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· Diagnostic procedures: laparoscopy, hysterosalpin-
gography
Diagnostic approach to amenorrhea implies diagno-
sis by exclusion. Pregnancy test is recommended as the
first step in evaluating any woman with amenorrhea.
Physical examination as the next step should begin with
evaluation of pubertal development and careful genital
examination.
Progesterone challenge test consists of oral adminis-
tration of 10 mg medroxyprogesterone for 5 days. If with-
drawal bleeding occurs, the amenorrhea is most likely due
to anovulation. If there is no bleeding, estrogen status
should be assessed. Once pregnancy and anatomical ab-
normalities have been excluded, all of the remaining
causes of amenorrhea are associated with anovulation due
to hypothalamic, pituitary, or ovarian disease. Determin-
ing the site of defect is clinically important because it
determines the appropriate therapeutic regimen.
Whenever hypothalamic lesions are suspected, de-
tailed evaluation of the hypothalamic-pituitary function
is indicated. The workup for Cushing’s syndrome should
be aimed first at establishing the diagnosis. The state of
hypercortisolism must be documented. Adult adrenal
glands secrete 10-30 mg cortisol daily on an average. The
secretion follows diurnal variation: cortisol levels tend to
be high early in the morning and low in the evening. To
determine the etiology of an elevated cortisol level, plasma
ACTH levels must be checked. ACTH secretion is evalu-
ated by the measurement of plasma ACTH and cortisol
levels. Cortisol measurement is a more useful screening
procedure: morning values of <10 mg/dl or <20 mg/dl un-
der stress conditions are suggestive of hypopituitarism. In
contrast to patients with primary adrenal insufficiency,
those with hypopituitarism may exhibit no appreciable
clinical symptoms and yet have nearly undetectable cir-
culating cortisol levels. A low or even normal ACTH level
in the presence of low cortisol level is highly indicative of
a primary adrenal disease. If cortisol levels are normal and
an intact response to ACTH is present, the hypothalamic-
pituitary axis should be evaluated39.
Hyperprolactinemia can decrease GnRH and pulsatile
secretion of LH and FSH40. As gonadotropin responses to
GnRH are normal in hyperprolactinemia, it appears that
elevated prolactin levels act at the hypothalamic level.
Hyperprolactinemia also inhibits positive estrogen feed-
back. If the hyperprolactinemia is caused by pituitary
prolactinoma (50% of all hyperprolactinemia cases), the
hormones show sustained hyperprolactinemia (often of a
marked degree), normal or suppressed serum gonadotro-
pin levels, and estrogen production. Prolactin elevation
caused by hypothalamic lesions rarely rise to greater than
150 ng/ml and usually are below 100 ng/dl. Similar eleva-
tions are also seen in patients with an empty sella. The pro-
lactin level correlates with pituitary tumor size. It is inter-
esting that prolactin levels can be increased in patients with
hypothalamic lesions while other hypothalamic-pituitary
functions (i.e. ACTH and TSH) are normal, although GH
levels and gonadotropin levels are also often suppressed.
This means that there is enough destruction or distortion
of the stalk and/or mediobasal hypothalamus to cause de-
ficiency of dopamine while permitting sufficient CRH and
TRH secretion. Idiopathic hyperprolactinemia usually
shows prolactin levels below 100 ng/ml41,42.
In case of premature ovarian failure, weekly serum
gonadotropin determinations and tests of urinary estro-
gen and progesterone excretion over a 6-week period will
provide a true baseline estimate of any ovarian follicular
activity. Karyotyping is performed in nulliparous patients.
Ovarian biopsy has been emphasized by some authors as
necessary to differentiate oocyte depletion from gonadot-
ropin-resistant ovary syndrome, which is allegedly ame-
nable to treatment43.
The diagnosis of polycystic ovary syndrome is based
on typical clinical features associated with an elevated
plasma LH/FSH ratio and increased plasma estrogen lev-
els. On ultrasonogrpahy, the syndrome is commonly found
in asymptomatic first-degree relatives of patients with the
disease.
Yearly bone mineral density measurement is a crucial
method that should be recommended for early detection
in all women of menopausal age.
However, dynamic testing of pituitary function will
often fail to differentiate between the hypothalamus and
pituitary as the specific primary locus of defect, and
neuroradiologic imaging by MRI or CT is almost always
required. The main indications for MRI or CT scanning
include primary hypogonadotropic hypogonadism, visual
field defects, headaches, other evidence of hypothalamic
or pituitary dysfunction, or other suggestive diseases. In
case of tumor (adenoma, prolactinoma, cysts) or lesion
(head trauma) induced amenorrhea, the essential exami-
nation is high resolution CT and MRI scanning. CT may
be better in detecting small lesions within the normal or
minimally enlarged gland. MRI is superior in visualizing
structures adjacent to the pituitary, which is often the most
significant issue. Abdominal CT scan will help separate
an adrenal neoplasm from primary adrenal hyperplasia.
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Therapy
Resumption of menstruation and fertility depends on
the etiology of amenorrhea. Conservative therapy is the first
choice. In patients with idiopathic, functional hypogo-
nadotropic amenorrhea, there are two goals: facilitating
ovulation to achieve fertility, and restoration of normal es-
trogen status to promote well-being and to prevent os-
teoporosis. The former can generally be achieved with cy-
clic estrogen and progesterone, whereas the latter may re-
quire clomiphene, GnRH, or gonadotropin therapy.
The ideal for patients with GnRH deficiency is
GnRH replacement therapy. Subcutaneous administra-
tion of 25 to 200 ng/kg GnRH every 2 hours by a por-
table pump leads to rapid rise in LH and FSH responses
to GnRH. Such therapy has led to ovulatory cycles in 80%
of patients, confirming the original hypothesis of a pri-
mary defect of GnRH secretion. An adequate level of sex
steroids is necessary for normal GH response in case of
growth hormone deficiency associated amenorrhea, and
sex hormone replacement is not used in these patients
before GH testing.
Therapy for osteoporosis includes exercise and drugs.
The drugs used to treat osteoporosis are classified into
antiresorptive and formation-stimulating agents. Antire-
sorptive agents such as calcium, estrogen, calcitonin, vita-
min D and biphosphonates, are used mainly for prevention
in perimenopausal women or for treatment of established
osteoporosis. Fluoride is the only formation-stimulating
agent. Currently, the only therapy that prevents the accel-
erated bone loss associated with menopause and other
causes of ovarian failure is estrogen replacement. This
therapy should be initiated within 4 to 6 years of menopause
to achieve its maximal effect. After that, irreversible bone
loss will have occurred.
In the management of hyperprolactinemia, bromocri-
ptine, a dopamine agonist, has been established as the drug
of choice. The hyperprolactinemia itself may impair go-
nadal function and so efforts may also be made to lower
prolactin levels with bromocriptine or another dopamine
agonist. Periodic monitoring of basal prolacin levels and
radiographic evaluation of sella turcica are indicated in all
subjects with hyperprolactinemia. Patients should be evalu-
ated at least quarterly and should undergo repeat CT or
MRI annually for at least additional 2 years. Control of
hyperprolactinemia using bromocriptine is followed by res-
toration of ovulatory menses and fertility, and abolition of
galactorrhea in 78% - 85% of all patients, and in more than
90% of those with idiopathic hyperprolactinemia. A dra-
matic reduction in tumor volume is seen in up to three
quarters of patients.
The regain of weight and cessation of exercise are the
best therapy for exercise and anorexia nervosa related amen-
orrhea. If weight gain is not practicable, consideration
should be given to estrogen replacement therapy to avoid
long-term sequels of hypoestrogenism. Treatment may
occasionally involve hospitalization for severe cachexia,
however, it primarily includes intensive psychotherapy. The
use of combined oral contraceptive and progestogen can
control irregular cycles of polycystic ovary syndrome.
Treatment components




Therapy for premature ovarian failure involves replace-
ment of cyclic estrogen and progesterone for the mainte-
nance of normal secondary sex characteristics and libido,
and avoidance of long-term sequels of hypoestrogenism.
High-dose exogenous gonadotropin therapy has occasion-
ally been associated with pregnancy, but the results are
generally disappointing. The majority of patients with
premature ovarian failure who subsequently conceive have
been exposed to estrogen. None of these therapies for
premature ovarian failure has been subjected to proper
prospective trial with due regard to the variable natural
history of premature ovarian failure and spontaneous
pregnancy rate.
Operative management of tumor (adenoma or prola-
ctinoma) is limited to subjects who are intolerant of or
resistant to conservative therapy (bromocriptine), and
those with tumors causing compressive symptoms, where
bromocriptine has had an inadequate effect. Evidence that
hypopituitarism results from pituitary compression in-
cludes a low serum prolactin level and lack of TSH re-
sponse to TRH. In such cases, pituitary function usually
does not improve with treatment. In patients with nor-
mal or elevated prolactin levels, pituitary function often
returns to normal with therapy17.
Selective removal of pituitary microadenomas by
transsphenoidal microsurgery corrects ACTH hypersecre-
tion and hypercortisolism in most patients. Surgical ex-
tirpation of the tumor commonly leads to worsening of
pituitary function, often resulting in complete panhypopi-
tuitarism and diabetes insipidus because of stalk sec-
Vrkljan M. et al. Health risk and Amenorrhea
310 Acta clin Croat, Vol. 40, No. 4, 2001
tion46,47. Radiotherapy is palliative therapy, and dysger-
minomas are the only tumors that are very radiosensitive,
thus radiotherapy being the preferred mode of treat-
ment47.
Follow-up
· patient monitoring: depends on the cause and treat-
ment chosen
· prevention/avoidance: maintenance of proper body
mass index
· possible complications: estrogen deficiency symp-
toms, osteoporosis, increased risk of endometrial
cancer in hyperestrogenism
· expected course/prognosis: reflecting the underly-
ing cause
Conclusions
Appropriate management of amenorrhea depends on
the underlying etiology. As described above, a number of
different pathologic processes can cause amenorrhea.
Even physiologic amenorrhea in third age of women’s life
can lead to serious health problems. Many symptoms in
climacteric women can be more important than the simple
clinical picture. Psychiatric problems (chronic depression),
cardiovascular disease, and osteoporosis are some of the
greatest problems, often encountered at general practitio-
ner offices. However, the problems faced by women with
amenorrhea are much deeper. Very important is the time
when substitution for estrogen deficit is initiated. A high
proportion of women with amenorrhea first experience
the symptoms of vaginal dryness and skin pruritus asso-
ciated with low estrogen levels. Estrogen substitution is
also helpful in postmenopausal women suffering from hot
flushes. Combined therapy with estrogen and progester-
one can protect women from severe malignancies (en-
dometrial carcinoma).
Untreated pituitary tumor (Cushing’s disease, prola-
ctinoma and nonfunctional tumors) frequently is a fatal ill-
ness. In many cases, death is the consequence of sustained
hypercortisolism and hyperprolactinemia and its compli-
cations, including hypertension, cardiovascular disease,
stroke, thromboembolism, and susceptibility to infection.
With current refinements in pituitary microsurgery and
radiotherapy, the great majority of patients with Cushing’s
disease can be successfully treated, and operative morbid-
ity and mortality are no longer present. The rates of suc-
cessful treatment vary but are improved by early diagnosis.
Therefore, this condition has heterogeneous clinical,
anatomical and biochemical features that result in clinical
difficulties hampering both diagnosis and therapy.
The menstrual cycle is relatively susceptible to exter-
nal influences, and changes in menses may be the earliest
sign of a decline or improvement in general health. Some
untreated cases may even have lethal outcome.
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Saæetak
S KAKVIM JE ZDRAVSTVENIM RIZIKOM UDRUÆENA AMENOREJA?
M. Vrkljan, M. BrkiÊ, A-M. ZeËeviÊ i P. TopiÊ
Amenoreja je jedan od najËe¹Êih simptoma u æenskoj patologiji. Ona moæe biti uzrokovana anatomskim nedostacima
izlaznoga trakta (maternica, u¹Êe maternice, rodnica) pa spada u djelokrug ginekologa, no moæe se zapaziti kod bolesti
nedostatka gonada (npr. Turnerov sindrom), hipopituitarizma (npr. Sheehanov sindrom), u bolesnika s tumorima hipofize koji
luËe prolaktin, kod Cushingova sindroma, hipertiroze, stresa, anoreksije nervosa, policistiËnih jajnika, te nakon prestanka
uzimanja oralnih kontraceptiva, poglavito u æena s prethodnim menstrualnim nepravilnostima u anamnezi. Endokrine
abnormalnosti mogu isto tako biti uzrokovane promjenama u odgovoru ciljnih tkiva na hormone. RazliËiti mehanizmi mogu
biti ukljuËeni u nastanak ovih bolesti. Endokrine ælijezde mogu biti o¹teÊene ili uni¹tene neoplazijom, infekcijama, krvarenjem,
autoimunim bolestima, te mnogim drugim uzrocima. NajËe¹Êi uzroci amenoreje su menopauza, trudnoÊa i dojenje. O¹teÊenja
hipotalamusa koja dovode do poremeÊenog luËenja hormona za otpu¹tanje mogu se oËitovati disfunkcijom hipofize, ¹to opet
rezultira funkcionalnim abnormalnostima razliËitih ciljnih organa. PoremeÊaji izvan te ælijezde mogu dovesti do pomanjkanja
hormona i postati oËitima, uz amenoreju kao jedan od simptoma. Procjena endokrinog statusa bolesnice temelji se na nalazima
iz anamneze, fizikalnog pregleda i laboratorijskih pretraga. Laboratorijski testovi mogu ukljuËivati mjerenje razina hormona
ili njihovih metabolita u plazmi ili mokraÊi u bazalnom stanju ili u odgovoru na provokativno testiranje. Kod sindroma
endokrine deficijencije hormoni se uglavnom daju kako bi se ispravila ta deficijencija. Kod sindroma s vi¹kom hormona
primjenjuju se razliËiti pristupi. Tumori koji pokazuju hiperfunkciju se odstranjuju kadgod je to moguÊe, a ponekad se uklanjanju
i hiperplastiËne ælijezde. U drugim pak sluËajevima daju se lijekovi za suzbijanje stvaranja hormona. Osteoporoza povezana s
menopauzom vodeÊi je zdravstveni problem povezan s amenorejom i treba ju ¹to ranije lijeËiti, tj. od poËetka razdoblja
prestanka menstruacije.
KljuËne rijeËi: Amenoreja, etiologija; Amenoreja, dijagnostika; Amenoreja, komplikacije; Osteoporoza, etiologija; Osteoporoza,
prevencija i kontrola
